Background
Methods
Patients
Tumor samples
TruSight™ oncology 500assay
Statistical analyses and disease evaluation
Results
Patient characteristics
All patients (N = 501) | |
---|---|
Age (year) | |
Median (range) | 59.7 (21–86) |
Sex | |
Male | 302 (60.3%) |
Female | 199 (39.7%) |
Tumor type | |
Colorectal cancer | 151 |
Gastric cancer | 116 |
Sarcoma | 60 |
Biliary tract cancer | 48 |
Pancreatic cancer | 42 |
Genitourinary cancer | 25 |
Other GI tract cancer | 22 |
Melanoma | 21 |
Hepatocellular carcinoma | 12 |
Rare cancer | 4 |
Tumor mutational burden (TMB) | |
TMB low | 443 (88.4%) |
TMB-high | 58 (11.6%) |
Microsatellite instability (MSI) | |
Non-MSI | 494 (98.6) |
MSI | 7 (1.4) |
PD-L1 (N = 225) | |
Positive | 101 (20.2) |
Negative | 124 (24.8) |
Homologous recombination (HR) | |
Deficiency | 375 (74.9%) |
Non-deficiency | 126 (25.1%) |
Receiving ICIs | |
Yes | 65 (13.0%) |
No | 436 (87.0%) |
Frequency of tumors with HRD according to type
Tumor type | HR deficiency | ICIs |
---|---|---|
Colorectal cancer (151) | 130 (86.1%) | 4 (2.6%) |
Gastric cancer (116) | 80 (69.0%) | 14 (12.1%) |
Sarcoma (60) | 39 (65.0%) | 3 (5.0%) |
Biliary tract cancer (48) | 36 (75.0%) | 5 (10.4%) |
Pancreatic cancer (42) | 32 (76.2%) | 1 (2.4%) |
Genitourinary cancer (25) | 23 (92.0%) | 12 (48.0%) |
Other GI tract cancera (22) | 11 (50.0%) | 1 (4.5%) |
Melanoma (21) | 12 (57.1%) | 20 (95.2%) |
Hepatocellular carcinoma (12) | 10 (83.3%) | 4 (33.3%) |
Rare cancerb (4) | 2 (50.0%) | 1 (25.0%) |
Total 501 | 375 (74.9%) | 65 (13.0%) |
Frequency of HRD according to HR-related genes
Correlations between HRD and disease progression in 65 patients treated with ICIs
Variables | Cases | PFS | |
---|---|---|---|
OR (95.0% CI) | P | ||
Age | |||
< 65 | 37 | ||
≥ 65 | 28 | 0.707 (0.394–1.267) | 0.244 |
Smoking | |||
No | 38 | ||
Yes | 27 | 1.037 (0.584–1.842) | 0.900 |
HRD | |||
0 (non-deficiency) | 12 | ||
1 (deficiency) | 53 | 1.376 (0.639–2.963) | 0.415 |
TMB | |||
Low | 50 | ||
High | 15 | 0.396 (0.182–0.859) | 0.019 |
Microsatellite instability | |||
Non-MSI | 61 | ||
MSI | 4 | 0.357 (0.086–1.486) | 0.157 |
PD-L1 by IHC | |||
Negative | 16 | ||
Positive | 15 | 1.000 (0.999–1.000) | 0.378 |
Variables | Cases | Response to ICIs | |
---|---|---|---|
Exp(β) (95.0% CI) | P | ||
Age | |||
< 65 | 37 | ||
≥ 65 | 28 | 1.157 (04,411–3.258) | 0.782 |
Smoking | |||
No | 38 | ||
Yes | 27 | 0.722 (0.251–2.077) | 0.545 |
HRD | |||
0 (non-deficiency) | 12 | ||
1 (deficiency) | 53 | 1.029 (0.273–3.881) | 0.967 |
TMB | |||
Low | 50 | ||
High | 15 | 6.333 (1.806–22.204) | 0.004 |
Microsatellite instability | |||
Non-MSI | 61 | ||
MSI | 4 | 6.632 (0.647–67.964) | 0.111 |
PD-L1 by IHC | |||
Negative | 16 | ||
Positive | 15 | 1.000 (0.999–1.001) | 0.431 |